Member Info for sadoldgit

Ideally the CPEI should be making inroads onto the treatment and control of the problems that Covid creates. Yes that means use of Jak1 and Tyk 2 inhibitors.

It's a money making lark for the pharma as vaccine fairly easy to put to market under the guise of helping humanity in a pandemic.

More close me thinks to lining their pockets and assisting the development and mutation of Covid 19 by subjecting it ti anti virals and vaccines. Unless eradication is 100% the virus will mutate

We have had Delta, now Omicron, What comes next Pi, then Epsilon, followed by Upsilon.

Always playing catchup and kicking the can down the road I feel.

What we have most likely is ground breaking and world beating. No announcements on TV of how good we claim to be prompted by numerous financial gifts offered to the media heirachary to promote 2nd rate treatments for their own financial gain.

Rant over for the day.

Regards and all have a great day.

Interesting up to date read. We have rubbished the Sinovac and Synopharm vaccines claiming the vaccines are of little to no effect at the same time claiming circa 70% for AZ and slightly less for Pfizer.
In reality all are sodding useless after a while.. Pharma's must love it. Next round of vaccinations. Was reading recently proposals of booster jabs at 6 month ( or even 3 month) intervals.

Two things look like being ruled out Herd immunity and lifelong vaccination safety.

Constant reinfection required for herd immunity. Benefit of vaccine which enables our immune systems to develop antibodies peaks and drops considerably ( 3 months).

Regards

What is the difference between the two?

Acute Respiratory Distress Syndrome (ARDS) and Severe Acute Respiratory Syndrome (SARS): Are We Speaking Different Languages?

'Acute respiratory distress syndrome (ARDS) and pneumonia are closely correlated in the critically ill patient. Whereas ARDS is often complicated by nosocomial pneumonia, pulmonary infection is also the most frequent single cause of ARDS. The prevalence of pneumonia during the course of ARDS seems to be particularly high, but whether persons with ARDS are more susceptible to pneumonia or simply have more risk factors remains unknown because of methodological limitations. Recent research suggests that host factors have a major bearing on the development of ARDS.
'To date, sepsis seems to be the principal link between pneumonia and ARDS ' However, prospective observational data on this supposed sequence are not available. ( Now bear in mind this info is taken from the Oxford academic in 2006)

Even at the above time it concludes
' Most recently, new respiratory viruses have received particular attention, and this review suggests that infections with coronavirus and avian influenza virus are associated with an exceptionally high incidence of lung injury and ARDS.

Note the ARDS sequence. pneumonia = sepsis= ARDS.

What is the point of my post you may well ask?
If or when we are likely ( very likely I would think) to be involved in clinical trials regarding Covid 19 then our point of therapy is indicative of target treatment.
You can be diagnosed with SARS ( severe respiratory distress syndrome)

'Pneumonia is swelling (inflammation) of the tissue in one or both lungs. It's usually caused by a bacterial infection. It can also be caused by a virus, such as coronavirus (COVID-19).

Now at the severe stage it is mooted that 1801 to be administered as a therapy. This would be after the assisatnce of oxygen but prior to ventilation I an thinking.

Are we now not treating ARDS and not SARS?

if this is the case and I believe it is so, then we are viable for a treatment in the very long term as a treatment for ARDS irrelevant of SARS although the latter is likely to lead to the former.

Don't just look at it covid 19 or bust in this respect. We in effect will be treating ARDS as that can lead to mortality.

Mortality rate for mild moderate to severe is 27% 32% and 45% respectively.

Regards and my tuppence worth for the night.

'

Any of the pieces of news will send SP above 6p. I would hazard a guess at toxicity being first closely followed by Agile should they chose to progress that route.
Covid at the moment forecast to last another 5 years which is not good for humanity but does point out the need for new treatments. However treatment for covid 19 which may prove financially beneficial is only a side play. Main aim is auto immune which has had years spent in the development and patent protection for and this is not going to change.

The question is who is going to want finance us investors or a pharma. Neither of these two aforementioned will want to miss out. It keeps Sareum in the safe haven by having options. Should the need arise we have proved we can raise in excess of 5 million pounds which makes us eligible for much higher financing. We will not be held over a barrel by a pharma.

Informal talks being going on for ages. Should not be long before formal discussions take place in which case that really does open the market up.

A likely best in class treatment for covid 19 on top of a best in class immuno therapy with little to no tox issues.

Evaluation of the tox data is required ( circa 4 weeks). News release of results. Just how interested are the parties involved in discussions at the moment. These people will be aware that we now have access to a considerable and alternative route for funding.
The longer they leave it the more they will have to pay, whether in upfront payments or milestones or combination of both.

Our compounds are second generation, highly selective, small molecule kinase inhibitors that are a massive step up from first generation large molecule with insufficient selectivity which causes adverse side effects.

Sareum have learned from the failure of others. That SKIL platform on its own must be nigh worth a third of market cap as it sits now.

I remember Tim in his presentation on Pro Active investor with Andrew Scott the smooth talking aussie 9Covid 19 around April,20200. Toxicity and black box warnings. We think these black box warnings may be associated with Jak 2 and Jak3. Of course they knew, that is why they went the Jak1 and Tyk2 route.

regards

Desamax and Ahfam, Goodmorning. My thoughts put out below.

With regards to a fast track and this would be with regards to severe covid cytokine storm, the stage 1 a trial may be of the same number but later stage 1 trial may involve many more and would definitely be fast tracked (Covid 19) as at this severe stage, the inhibitor would be used in a life or death situation.

Indicative of favourable toxicology outcome, Sareum are very confident. They will have had results but of course this data has to be supplied to governing bodies that decide. In this respect sareum will have a very, very good idea but cannot relay this as is down to governing and regulating bodies. Hence until formal acceptance they can say no more. However, they have raised money for Stage 1a trials so in a way that says it all really.

Via HNWI we have raised another 1.6 million.

Given that the preclinical work has been completed it must therefore be a stone cold certainty that we will enter phase1 trial.( Note the announcement of preclinical completed and further investment by HNWI a day later.. Far too coincidental me thinks.) The notification of CTA acceptance will propel the SP to new highs irrespective of the prolonged attempt by PH to suppress our market cap.
Yes a little while away. Don't count your chickens before they hatch it is said. There is an element of risk. This is true. We have overcome the elements of risk before. Nothing is certain until proved.

It is time for the science to do the walking and not the talking.. Our science is good, damn good.

Regards and the sun is over the yard arm somewhere in the world so beer o clock. ( nightshifts finished)

I am sure someone posted on here just now with regards to how many people take part in stage one a clinical trials.
This is an excerpt taken from the FDA guidlines which are very similar to ours.

Clinical trials, also known as clinical studies, test potential treatments in human volunteers to see whether they should be approved for wider use in the general population. A treatment could be a drug, medical device, or biologic, such as a vaccine, blood product, or gene therapy. Potential treatments, however, must be studied in laboratory animals first to determine potential toxicity before they can be tried in people. Treatments having acceptable safety profiles and showing the most promise are then moved into clinical trials.

Done at hospitals and research centres around the country, clinical trials are conducted in phases. Phase 1 trials try to determine dosing, document how a drug is metabolized and excreted, and identify acute side effects. Usually, a small number of healthy volunteers (between 20 and 80) are used in Phase 1 trials.

Phase 2 trials include more participants (about 100-300) who have the disease or condition that the product potentially could treat. In Phase 2 trials, researchers seek to gather further safety data and preliminary evidence of the drug's beneficial effects (efficacy), and they develop and refine research methods for future trials with this drug. If the Phase 2 trials indicate that the drug may be effective--and the risks are considered acceptable, given the observed efficacy and the severity of the disease--the drug moves to Phase 3.

I would hazard a guestimate of around 30 to 50 volunteers here in the UK.

Regards

At the very least it has strengthened our financial position. I do not in any way find this new raising in any way negative, Effectively I see it at buying in at a 40% discount. I am sure this will not be the last raising of funds in this format. It enables us to finance early trials on what may be regarded as the best Tyk2 Jak1 kinase inhibitors currently available. Price has taken a bit of a tumble yes. HNWI will know a tad more than we know. whether they make 200% profit or 500% profit over their expected return time is irrelevant. Time has moved on and we are now approaching probable milestone payments from Sierra in near future. half a million is not mush but more importantly once struck is indicative of continuing milestone payments of which sareum are eligible for 70 million. All warming up nicely. i sincerely hope that Sierra will on licence momoletonib in next few months or give indications thereof.Regards

I am of the opinion that Peel .unt are suprressing the price to keep it low. consolidation will be all about achieving a price per share for example 1 pound which at the moment approx 20 to 1. When it were 8p a share 13 to one.
Effectively dragging the price down for their clients whoever they may be ( but certainly not Sareum). the amount of trades, the price per trade and the period that PH have been brokering will all play a part in the consolidation I feel. They will have clients that will want in as cheap as possible.

It is the inevitable price for moving us from a penny share to a pound share.

Ideally need some 5hit hot news from the other side of the pond from Sierra, fairly soon.

They cant steal your shares but they can try and rattle you into selling, The Science is good remember that. Once consolidation is made then it seriously opens up the probability of a buyout I feel. However like the PH client they will want in on the least to be paid.
PH have knocked around 80 million off the market cap so far. Under priced at the moment as reflected in the amount of buys whenever the market sentiment drops the SP.

Regards and dont fret. if you dont sell they wont be getting your shares cheap only to rocket up on news of a deal or licensing. Investment companies will have their beady little eyes on this too.

Agree CobaltBlue. There is a degree of kudos in not being looked at as a penny share. it will attract investors and interested partners.

We will break 6p easily today I feel.

Take a look at patent EP2634185A1 section 0013

Overexpression of TYK2 kinase has been implicated in the development of some disease states. For example, elevated levels of TYK2 were found in patients suffering from progressive pulmonary sarcoidosis (Schischmanoff et al., Sarcoidosis Vasc. Diffuse., 2006, 23(2), 101-7).

There are treatments but at present no known cure.

Regards

Good post TJB.

It is of paramount importance that we have water tight patent protection in place.
some aspects of our Tyk 2 compounds were patented over 12 years ago. Development takes time and eats into patent time remaining. These compound protections are now further extended/ superseded and enhanced by our latest patents.
Such is the importance of these patents that it cannot be emphasised enough in maximising the true monetary value of our unique TYk2 Jak compounds.
Another hurdle well and truly jumped.

Regards

We are already protected with A European patent as shown below. My opinion for what it is worth, is that this is additional protection for the crystallisation of a compound. A long period of protection being 17 years from date of granting.

Belt and braces on patent protection.

1.
PHARMACEUTICAL COMPOUNDS
WO2018073438A1 • 2018-04-26 • SAREUM LTD
Earliest priority: 2016-10-21 • Earliest publication: 2018-04-26
The invention provides a compound for use in the treatment of T-Cell Acute Lymphoblastic Leukaemia (T-ALL), the compound having the formula (1): or being a pharmaceutically acceptable salt thereof; wherein: n is 0, 1 or 2; Ar1 is selected from an optionally subtituted phenyl, pyridyl, thienyl and furanyl; Q1 is selected from C(=O), S(=O) and SO2; A is absent or is NR2; R1 is selected from: -hydrogen; -an optionally substituted C1-6 non-aromatic hydrocarbon group; and -optionally substituted 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are 1 nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings; R2 is selected from hydrogen and C1-4 alkyl; or NR1 R2 forms an optionally substituted 4- to 7-membered non-aromatic nitrogen- containing heterocyclic ring optionally containing a second heteroatom ring member selected from nitrogen and oxygen.

As shown above the compound is protected but not the manufacturing of. ( hence we can safely summise this added protection ties in very nicely with 100% purity of a compound to be manufactured in capsule form.

Not ground breaking news as such, but indicative of crossing the tees and dotting the eyes for at least an on licence or partnership in the not too distant future.

Regards.

Celtic. I think that is the case of hitting the proverbial nail on the proverbial head. it does to a certain extent indicate the limits of vaccines. It does open up the prospect of suitable immuno kinase inhibitors for treatment of cytokine storm.. There are very few around!

i not believe Covid is entirely natural. Reverse engineered for what ever reason and a constantly evolving virus that will prove problomatic for years to come.

Complete eradication is impossible in the foreseable future.

Regards

Regards.

Good that deal is made with Volz. Covid is not leaving anytime soon.

Research on using air filter machines on Covid-19 wards In November 2021, a research team at Addenbrooke’s Hospital and the University of Cambridge reported that they were able to use HEPA filter/UV steriliser air purifiers to remove most airborne traces of SARS-CoV-2 on surge wards at the hospital. The air purifiers also successfully filtered out other bacterial, fungal and viral bioaerosols (airborne particles containing living organisms). Intensive care consultant at Addenbrooke’s Hospital Dr Vilas Navapurkar, who led the study, told us: ‘We can remove SARS-CoV-2 and other infecting potential organisms from the air. We can measure how much is there in that proportion of air that’s breathable into the lungs that triggers injury. It’s the science of measuring the air that’s key here.’

Worked with Hepa filters most of my life. with the addition of nano particle should prove extremely promising and a rosy future for NNN. Still hold a few million shares here which I had written off. Happy to hold as in no dire need for funds.

All the best to the LTH. in the end you will make impressive gains.

Regards

Pfizer
https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history

A quiet night indeed. Pharma's are like banks greed and control freaks. They will push vaccines as over a 2 out of 3 chance being accepted and no lead for long research and development treatments associated with therapeutic treatments.

Always will be vaccines playing the part of catch up. Never in front always will be one pace behind. Big pharma's coining it.

One thing that does intrigue me is that in a safety trial (which will be in healthy adults) is that when SDC1801 is trialled will these persons show signs of no cytokine storm ill effects should they be unfortunate but very likely to contract covid 19 whatever strain?

It would make phenomenal interesting investigation results, albeit in a safety trial only.

Regards good night and good morning.

SD,With regards our dna and make up i was taught that their were 8 essential amino acids and 14 non essential. Arginine and ornithine were two that weight lifters used. Ornithine being a derivative of arginine but works slightly different. I will look into when time permits and look up which now I have mostly forgotten essential and non essential amino acids.

Regards

I am glad you used the word tyrosine.

SD I think you will find Jimmy does not know or cant remember what he says.

A post from April 2020. What he says does not add up.

Your having a laugh, tell the investers who hot roped in at 3- 4 p.
Years ago.
Not a chance of recovery for them, and if this ever, that's ever gets any where near 2-3 p there will be no control of the amount of investers who are so desperate to claw there long tied up money back.
This stock is just a joke,
30-36 ish get in, 50-70 ish get out.
I've done it for years,

That Jimmy is full of Ertha.

Regards.

You are welcome to my thoughts Ahfam as many others.

Far too busy at moment with work @ circa 80 hrs a week. But I feel it puts me outside the gold fish bowl as opposed to being blinkered.

Sp likely to fall graduallly on no news. New broker looking after his clients ( not us) will use trade amounts to establish MK value to sell to its clientele. They are not interested in what Sareum does as all they are is a middle man. AIM get hammered by these people.

The science to me looks stronger than ever before. The attention to detail in getting it right will prevail.

it is Sareums aim to sell at late preclinical or early stage ciinical an objective. Failing that/

However look at Sierra Oncology. To them SRA737 is proving far too good to let it go. Excellent results with likewise excellent ADMET. They cannot afford to develop as have no funds, Alternative fund raising as are Sar now doing.

Should momoletonib prove prosperous and I do believe it will be, then SRA 737 gets a kick which lines us up for milestone payments. Any announcement of such will be worth more than the milestone payment. Sareum has a likely revenue. Once achieved Sareum will have an income. Interesting point here if milestone payment made will significantly up Sareum SP. What price then does the new broker attract investors?

All comes down to money. Big phamas with loaded pockets will not pay anywhere near the value it is worth. Not interested in treatments. As long as their product rakes in millions they will deter or prevent any party that is likely to upset this.

Imagine a big pharma with SDC 1801 and 1802 in its own pipeline with unlimited funds. How much would you put a value on? The mind boggles, the world is corrupt.

Sareum has something special. As Tim said years ago we are not biologists, but what we are very good at is chemistry ( from a very modest man). A genius I would say.

It will come to fruition. Sareum will not be pushed out. Sareum have the abiliy to raise funds.

As an analogy I feel at the moment, sitting down and playing poker and there they have, a good hand as do many others,. But of course you need funds to play life's gain, There they sit Sareums in all its splendour with a Royal flush.

All joking aside. What we have is good. Very, very good. That is my understanding of the science. of course Tim and co and the HNWI are party to, streets ahead of me on their knowledge.

I wonder if they ever read these posts that are put on here,

Regards and a super future to all invested here.

With regards to toxicity results, In my very honest opinion, is that they will be good but how good by confirmation of results we just don't know until received. Much work has been done in in vitro ( glass petri dishes) or in vivo which is animal and in this case humanised mice.
This is where years of research and getting it pretty well spot on is all about.

I cannot see any reason as to why the toxicity results would not meet the criteria to go into human trials. Human trials are the next step up. MTD was attempted at 30 times treatment levels with no observed adverse side effects.
Since treatment levels were given at between 12.5 mg total body dose to a maximum 10 mg per kilo up to 100 kg body weight ie 1000mg or 1 gramme. I myself await eagerly of the result. Mice do not weigh much compared to a human being.

if we take treatment to establish a MTD it would appear that 30x 12.5 equalling 375mg ( that looks pretty short even at minimum doseage) that the MTD would be based on 30 x 10 mg per kilo equating to a 100kg person receiving 30g. This in preclinical did not create ant adverse effects, Outstanding and of course very difficult to test to extreme with the 'then as were manufacturing. and methods of oral administration to the body. ( Remember the difficulties from Tim expressing concerns as to how sufficient quantities of compound could be manufactured to establish an MTD. ' Perhaps', Tim did say we looking at 100 times, but no info to suggest they ever reached this target.

Bloody good job they have decided to manufacture a capsule. Treatment of targets of course would also be dose dependant.

100% purity of formulation can be guaranteed by the patented 'crystalline formulation of a compound.'

That my pennies worth on this one.
I will add
Il-6 not without its problems and complete irradication of IL-6 with downstream signalling can induce succeptability to risk of infection.

Since ratios are all important ,as is also the dose dependency on attempting to achieve a MTD I believe we will pass with flying colours not only the preclinical toxicology studies to take us into human trials but also pretty well guaranteed a more than adequate safety profile with associated side effects in first stage clinical trials.

The announcement of toxicology results should enable us to go into phase 1 human trials , I have no fear that this will not be achieved.

As for SP, a rapid trip north which may fall slightly until news of stage 1 trials completing. Of course it would be prudent not to rule out with what is happening over the other side of the pond with regards to SRA 737.

Regards